ArticleCancers2020
Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Exosomes liquid biopsy in Lymphoma precision medicine: applications and challenges.Cancer cell international · 2026Review
- Mesenchymal stem cell-derived exosomes in myocardial infarction repair: therapeutic potential and scaffold-based delivery strategies.Frontiers in pharmacology · 2026Review
- Prognostic value of the pre-treatment SUVmax ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma.Scientific reports · 2025Article
- Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics.Theranostics · 2025Review
- Prognostic Value ofKorean journal of radiology · 2024Article
- Therapeutic challenges in peripheral T-cell lymphoma.Molecular cancer · 2024Review
- Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles.Frontiers in oncology · 2023Review
- Article
- Review
- The identification of gene signatures in patients with extranodal NK/T-cell lymphoma from a pair of twins.BMC cancer · 2021Article
- Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.Life (Basel, Switzerland) · 2021Review
- Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review).International journal of oncology · 2021Review
- Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma.Frontiers in oncology · 2021Review
- Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis.Journal of Cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Exosomes containing microRNAs (miRNAs) might have utility as biomarkers to predict the risk of treatment failure in extranodal NK/T-cell lymphoma (ENKTL) because exosomal cargo miRNAs could reflect tumor aggressiveness. We analyzed the exosomal miRNAs of patients in favorable (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.